Evidence map›Paper›PMID 35472072›Full record

ArticlePLoS pathogens2022

Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.

Jillian A Bristol, Joshua Brand, Makoto Ohashi, Mark R Eichelberg, Alejandro Casco, Scott E Nelson, Mitchell Hayes, James C Romero-Masters, Dana C Baiu, Jenny E Gumperz and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Reconstructing EBV reactivation and DNA damage response kinetics in morphologic pseudotime.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jillian A BristolDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0001-6109-8126
Joshua BrandDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0002-4578-4860
Makoto OhashiDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Mark R EichelbergDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Alejandro CascoDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Scott E NelsonDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0003-0084-1355
Mitchell HayesDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
James C Romero-MastersDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0001-6871-0568
Dana C BaiuDepartment of Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0001-7542-5300
Jenny E GumperzDepartment of Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0003-1852-2192
Eric C JohannsenDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Huy Q DinhDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0002-3307-1126
Shannon C KenneyDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0002-9655-6526
University of Wisconsin–Madison · US

Funding

Visualizing EBV and HCMV DNA Dynamics During InfectionP01CA022443 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Paul F. Lambert · 1985 to 2026
$53.1M
Training in Cancer Biology Training GrantT32CA009135 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SUGDEN, WILLIAM M. · 1985 to 2024
$10.4M
Effects of EBV Type on Viral ReactivationR01AI147060 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KENNEY, SHANNON CELESTE · 2019 to 2023
$2.6M
Role of EBV Lytic Infection in Viral TumorigenesisR01CA229673 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KENNEY, SHANNON CELESTE · 2019 to 2023
$2.5M
Mechanisms of iNKT cell anti-viral adjuvancyR01AI136500 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI GUMPERZ, JENNY E. · 2018 to 2022
$1.9M
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized MiceR01CA232616 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KENNEY, SHANNON CELESTE · 2018 to 2022
$1.9M
NCI NIH HHS P01 CA022443NCI NIH HHS R01 CA229673NCI NIH HHS R01 CA232616NCI NIH HHS T32 CA009135NIAID NIH HHS R01 AI136500NIAID NIH HHS R01 AI147060
6 · The paper itself

Abstract

Humans are infected with two types of EBV (Type 1 (T1) and Type 2 (T2)) that differ substantially in their EBNA2 and EBNA 3A/B/C latency proteins and have different phenotypes in B cells. T1 EBV transforms B cells more efficiently than T2 EBV in vitro, and T2 EBV-infected B cells are more lytic. We previously showed that both increased NFATc1/c2 activity, and an NFAT-binding motif within the BZLF1 immediate-early promoter variant (Zp-V3) contained in all T2 strains, contribute to lytic infection in T2 EBV-infected B cells. Here we compare cellular and viral gene expression in early-passage lymphoblastoid cell lines (LCLs) infected with either T1 or T2 EBV strains. Using bulk RNA-seq, we show that T2 LCLs are readily distinguishable from T1 LCLs, with approximately 600 differentially expressed cellular genes. Gene Set Enrichment Analysis (GSEA) suggests that T2 LCLs have increased B-cell receptor (BCR) signaling, NFAT activation, and enhanced expression of epithelial-mesenchymal-transition-associated genes. T2 LCLs also have decreased RNA and protein expression of a cellular gene required for survival of T1 LCLs, IRF4. In addition to its essential role in plasma cell differentiation, IRF4 decreases BCR signaling. Knock-down of IRF4 in a T1 LCL (infected with the Zp-V3-containing Akata strain) induced lytic reactivation whereas over-expression of IRF4 in Burkitt lymphoma cells inhibited both NFATc1 and NFATc2 expression and lytic EBV reactivation. Single-cell RNA-seq confirmed that T2 LCLs have many more lytic cells compared to T1 LCLs and showed that lytically infected cells have both increased NFATc1, and decreased IRF4, compared to latently infected cells. These studies reveal numerous differences in cellular gene expression in B cells infected with T1 versus T2 EBV and suggest that decreased IRF4 contributes to both the latent and lytic phenotypes in cells with T2 EBV.

Indexed as

B-LymphocytesBurkitt LymphomaHerpesvirus 4, HumanInterferon Regulatory FactorsHumansInterferon Regulatory Factor-4PhenotypeViral ProteinsInterferon Regulatory Factor-4Interferon Regulatory FactorsViral Proteins

Identifiers

PMID35472072
PMCPMC9041801
OpenAlexW4225001778

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.